Nia Tatsis, Ph.D., joined Vertex in 2017 and is the company’s Executive Vice President and Chief Regulatory and Quality Officer. In this role, she provides global regulatory leadership and is responsible for managing all regulatory interactions and quality assurance involving the research and development, manufacturing, and commercialization of Vertex’s transformational medicines. In addition to creating and executing the company’s global regulatory strategy, Dr. Tatsis also manages a worldwide team of regulatory professionals.
Prior to joining Vertex, Dr. Tatsis held positions of increasing responsibility at pharmaceutical companies such as Sanofi, Stemnion, Pfizer, and Wyeth. Most recently, she was Vice President, Head of Global Regulatory Affairs, at the Sanofi Genzyme Business Unit focused on Inflammation/Immunology, Rare Disease, Multiple Sclerosis, Ophthalmology, Neurology, and Oncology/Immuno-Oncology.
Dr. Tatsis also worked as an associate staff scientist and research fellow in Immunology and Vaccine Development at the Wistar Institute and completed a post-doctoral research fellowship in Immunology at Thomas Jefferson University. She received her Ph.D. in Cell and Molecular Biology from the University of Vermont and also holds a B.S. in Biology from Temple University.
What is Ourania Tatsis' net worth?
The estimated net worth of Ourania Tatsis is at least $29.80 million as of February 27th, 2025. Dr. Tatsis owns 58,539 shares of Vertex Pharmaceuticals stock worth more than $29,798,693 as of March 25th. This net worth approximation does not reflect any other investments that Dr. Tatsis may own. Learn More about Ourania Tatsis' net worth.
How do I contact Ourania Tatsis?
The corporate mailing address for Dr. Tatsis and other Vertex Pharmaceuticals executives is 50 NORTHERN AVENUE, BOSTON MA, 02210. Vertex Pharmaceuticals can also be reached via phone at (617) 341-6100 and via email at investorinfo@vrtx.com. Learn More on Ourania Tatsis' contact information.
Has Ourania Tatsis been buying or selling shares of Vertex Pharmaceuticals?
Over the course of the past ninety days, Ourania Tatsis has sold $505,512.14 in Vertex Pharmaceuticals stock. Most recently, Ourania Tatsis sold 530 shares of the business's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $475.34, for a transaction totalling $251,930.20. Following the completion of the sale, the executive vice president now directly owns 58,539 shares of the company's stock, valued at $27,825,928.26. Learn More on Ourania Tatsis' trading history.
Who are Vertex Pharmaceuticals' active insiders?
Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), E. Morrey Atkinson, III (EVP), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vertex Pharmaceuticals?
During the last year, insiders at the pharmaceutical company sold shares 20 times. They sold a total of 64,463 shares worth more than $30,955,261.94. The most recent insider tranaction occured on March, 10th when EVP David Altshuler sold 3,231 shares worth more than $1,615,500.00. Insiders at Vertex Pharmaceuticals own 0.2% of the company.
Learn More about insider trades at Vertex Pharmaceuticals. Information on this page was last updated on 3/10/2025.
